The Simcyp™ division was founded in 2001 by Professors Geoff Tucker and Amin Rostami-Hodjegan as a spin-out company from the University of Sheffield, UK. Simcyp was acquired by Certara in 2012 and has experienced dynamic growth, employing over 130 people including scientists, software developers, and support staff.
The Simcyp division maintains strong academic links, and our team conducts internationally-recognized, cutting-edge research and development. Certara’s in-house expertise also allows the team to provide scientific, software development, bespoke consultancy services, and education programs around the world.
Today, 37 biopharmaceutical companies all over the world are members of the Simcyp Consortium. As the Simcyp Consortium helps guide scientific development of the Simcyp Simulator, it ensures the software continues to meet and exceed industry needs.
Each year, the Simcyp Consortium of leading pharmaceutical and biotechnology companies meet to discuss the latest scientific developments in the area of modeling and simulation and guide the future development of the Simcyp Population-based Simulator.
Certara offers consultancy services on all aspects of drug ADME and PK/PD data analysis and interpretation. Our scientists advise on the design of PBPK models and deliver independent analysis, interpretation, and reports.
This service is ideally suited to those who do not have the resources, expertise, or time to use our Simcyp Simulator, QSP, or QSTS directly.
Certara’s Simcyp division offers hands-on workshops on various aspects of model-based drug development. The full week-long workshops cover the incorporation of population variability into the mechanistic prediction of PK and modelling of PK-PD whereas the 2-day focused workshops cover in-depth some of the major topics in model-based drug development. We also offer bespoke training which can be tailered to your specific requirements.